Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer

Autor: Vrede, S. W., Van Weelden, Willem Jan, Visser, N. C. M., Bulten, Johan, van der Putten, Louis J. M., van de Vijver, Koen, Santacana Espasa, Maria, Colàs Campàs, Laura, Gil-Moreno, Antonio, Moiola, Cristian P., Mancebo, Gemma, Krakstad, Camilla, Trovik, Jone, Haldorsen, Ingfrid S., Huvila, Jutta, Koskas, Martin, Weinberger, Vit, Bednarikova, M., Hausnerova, Jitka, van der Wurff, Anneke A. M., Matias-Guiu, Xavier, Amant, Frederic, ENITEC Consortium, Snijders, Marc P. L. M., Küsters-Vandevelde, Heidi V. N, Reijnen, Casper, Pijnenborg, Johanna M. A.
Přispěvatelé: Institut Català de la Salut, [Vrede SW] Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands. Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands. [van Weelden WJ, van der Putten LJM] Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands. [Visser NCM] Department of Pathology, Stichting PAMM, Eindhoven, the Netherlands. Department of Pathology, Radboud university medical center, Nijmegen, the Netherlands. [Bulten J] Department of Pathology, Radboud university medical center, Nijmegen, the Netherlands. [van de Vijver K] Department of Pathology, Ghent University Hospital, Cancer Research Institute Ghent (CRIG), Ghent, Belgium. [Colas E, Moiola CP] Grup de Recerca Biomèdica en Ginecologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERONC, Barcelona, Spain. [Gil-Moreno A] Servei de Ginecologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERONC, Barcelona, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERONC, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, CCA - Imaging and biomarkers, Obstetrics and Gynaecology, ARD - Amsterdam Reproduction and Development
Rok vydání: 2021
Předmět:
0301 basic medicine
Oncology
IMPACT
PREDICTION
Estrogen receptor
factores biológicos::biomarcadores::marcadores tumorales [COMPUESTOS QUÍMICOS Y DROGAS]
0302 clinical medicine
STAGE
Medicine and Health Sciences
Medicine
Stage (cooking)
Lymph node
Outcome
Obstetrics & Gynecology
Obstetrics and Gynecology
Immunohistochemistry
Women's cancers Radboud Institute for Health Sciences [Radboudumc 17]
3. Good health
medicine.anatomical_structure
030220 oncology & carcinogenesis
CELL-ADHESION MOLECULE
SURVIVAL
Biomarker (medicine)
Life Sciences & Biomedicine
EXPRESSION
medicine.medical_specialty
CARCINOMA
Endometrial carcinoma
03 medical and health sciences
All institutes and research themes of the Radboud University Medical Center
Internal medicine
CURETTAGE
Progesterone receptor
Carcinoma
Biological Factors::Biomarkers::Biomarkers
Tumor [CHEMICALS AND DRUGS]
Diagnosis::Prognosis [ANALYTICAL
DIAGNOSTIC AND THERAPEUTIC TECHNIQUES
AND EQUIPMENT]
diagnóstico::pronóstico [TÉCNICAS Y EQUIPOS ANALÍTICOS
DIAGNÓSTICOS Y TERAPÉUTICOS]
Lymph node metastasis
Science & Technology
Endometri - Càncer - Prognosi
RECEPTOR
business.industry
Endometrial cancer
Marcadors tumorals
Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms
Female::Uterine Neoplasms::Endometrial Neoplasms [DISEASES]
Biomarker
medicine.disease
030104 developmental biology
L1CAM
business
neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias uterinas::neoplasias endometriales [ENFERMEDADES]
Zdroj: Gynecologic Oncology, 161, 787-794
Gynecologic Oncology
Repositorio Abierto de la UdL
Universitad de Lleida
Scientia
GYNECOLOGIC ONCOLOGY
Gynecologic Oncology, 161, 3, pp. 787-794
Gynecologic oncology, 161(3), 787-794. Academic Press Inc.
ISSN: 0090-8258
1095-6859
Popis: Objective. Pre-operative immunohistochemical (IHC) biomarkers are not incorporated in endometrial cancer (EC) risk classification. We aim to investigate the added prognostic relevance of IHC biomarkers to the ESMOESGO-ESTRO risk classification and lymph node (LN) status in EC. Methods. Retrospective multicenter study within the European Network for Individualized Treatment of Endometrial Cancer (ENITEC), analyzing pre-operative IHC expression of p53, L1 cell-adhesion molecule (L1CAM), estrogen receptor (ER) and progesterone receptor (PR), and relate to ESMO-ESGO-ESTRO risk groups, LN status and outcome. Results. A total of 763 EC patients were included with a median follow-up of 5.5-years. Abnormal IHC expression was present for p53 in 112 (14.7%), L1CAM in 79 (10.4%), ER-in 76 (10.0%), and PR-in 138 (18.1%) patients. Abnormal expression of p53/L1CAM/ER/PR was significantly related with higher risk classification groups, and combined associated with the worst outcome within the 'high and advanced/metastatic' risk group. In multivariate analysis p53-abn, ER/PR-and ESMO-ESGO-ESTRO 'high and advanced/metastatic' were independently associated with reduced disease-specific survival (DSS). Patients with abnormal IHC expression and lymph node metastasis (LNM) had the worst outcome. Patients with LNM and normal IHC expression had comparable outcome with patients without LNM and abnormal IHC expression. Conclusion. The use of pre-operative IHC biomarkers has important prognostic relevance in addition to the ESMO-ESGO-ESTRO risk classification and in addition to LN status. For daily clinical practice, p53/L1CAM/ER/ PR expression could serve as indicator for surgical staging and refine selective adjuvant treatment by incorporation into the ESMO-ESGO-ESTRO risk classification. (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/). sion was present for p53 in 112 (14.7%), L1CAM in 79 (10.4%), ER- in 76 (10.0%), and PR- in 138 (18.1%) patients. Abnormal expression of p53/L1CAM/ER/PR was significantly related with higher risk classification groups, and combined associated with the worst outcome within the 'high and advanced/metastatic' risk group. In multivariate analysis p53-abn, ER/PR- and ESMO-ESGO-ESTRO 'high and advanced/metastatic' were independently associated with reduced disease-specific survival (DSS). Patients with abnormal IHC expression and lymph node metastasis (LNM) had the worst outcome. Patients with LNM and normal IHC expression had comparable outcome with patients without LNM and abnormal IHC expression. Conclusion. The use of pre-operative IHC biomarkers has important prognostic relevance in addition to the ESMO-ESGO-ESTRO risk classification and in addition to LN status. For daily clinical practice, p53/L1CAM/ER/ PR expression could serve as indicator for surgical staging and refine selective adjuvant treatment by incorpora
Databáze: OpenAIRE
Externí odkaz: